The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer

Gynecologic Oncology

Volumn 134, Issue 2, 2014, Pages 338-345

  Ford, C E ^a   Punnia Moorthy, G ^a   Henry, C E ^a   Llamosas, E ^a   Nixdorf, S ^b   Olivier, J ^a   Caduff, R ^c   Ward, R L ^a   Heinzelmann Schwarz, V ^b,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Epithelial ovarian cancer; Metastasis; Wnt signalling; Wnt5a; Catenin

Indexed keywords

EPITHELIAL OVARIAN CANCER; METASTASIS; WNT SIGNALLING; WNT5A; Β-CATENIN;

EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UP-REGULATION; WNT PROTEINS;

EID: 84905561583     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.06.004     Document Type: Article

References (19)

1. C.A. AIHW Gynaecological cancers in Australia: an overview Cancer series no. 70. Vol. CAN 66 2012 AIHW Canberra
2. R. Vang, IeM. Shih, and R.J. Kurman Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Adv Anat Pathol 16 5 2009 267 282
3. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 10 11 2010 803 808
4. C.E. Ford et al. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells PLoS One 8 1 2013
5. F. Jacob et al. Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients PLoS One 7 2 2012 e31885
6. R. van Amerongen, A. Mikels, and R. Nusse Alternative wnt signaling is initiated by distinct receptors Sci Signal 1 35 2008 re9
7. S.L. McDonald, and A. Silver The opposing roles of Wnt-5a in cancer Br J Cancer 101 2 2009 209 214
8. M. Nishita et al. Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells Trends Cell Biol 20 6 2010 346 354
9. J. Li et al. WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma Cancer Biol Ther 10 6 2010 617 624
10. J. Ying et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer Clin Cancer Res 14 1 2008 55 61
11. X. He et al. A member of the Frizzled protein family mediating axis induction by Wnt-5A Science 275 5306 1997 1652 1654
12. A.J. Mikels, and R. Nusse Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context PLoS Biol 4 4 2006 e115
13. C.E. Ford et al. The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis Int J Cancer 2012 10.1002/ijc.27984
14. J. Vandesompele et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 7 2002 RESEARCH0034
15. L. Badiglian Filho et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer Oncol Rep 21 2 2009 313 320
16. C. Peng et al. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer Int J Gynecol Cancer 21 2 2011 280 288
17. H.Y. Su et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway Int J Cancer 127 3 2009 555 567
18. E.J. Ekstrom, V. Sherwood, and T. Andersson Methylation and loss of secreted frizzled-related protein 3 enhances melanoma cell migration and invasion PLoS One 6 4 2011 e18674
19. K.S. Carmon, and D.S. Loose Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells Mol Cancer Res 6 6 2008 1017 1028